Literature DB >> 12911941

Prognostic factors in adult acute lymphoblastic leukemia.

Xavier Thomas1, Quoc-Hung Le.   

Abstract

The prognosis of patients with acute lymphoblastic leukemia (ALL), treated with modern chemotherapeutic regimens, is dependent on a number of variables. The major prognostic factors for survival in adult ALL are age, cytogenetic abnormalities, immunologic subtype, white blood cell (WBC) count, and time to achieve complete remission (CR). Determination of these factors is crucial for adapting post remission therapy in adult ALL. Indeed, risk-adapted strategies based on those biologic and clinical features are currently being applied to improve survival. In this review, we report the different prognostic factors described in adult ALL and discuss the controversies in current adult ALL management in relation with these different features. The data reported are derived from the medical literature and from the experience of the authors. Prognostic factors appear to be time-dependent. This emphasizes their determination according to the phase of treatment. The use of time-segmented multivariate analysis able to distinguish prognostic factors associated with the induction phase and those associated with the post-induction phase of treatment seems suitable to define accurately prognostic models.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12911941     DOI: 10.1080/1024533031000153621

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  5 in total

1.  A rare case of acute lymphoblastic leukaemia in pregnancy- unique maternal-fetal challenges.

Authors:  Shamim Khandaker; Shabana Munshi
Journal:  J Clin Diagn Res       Date:  2014-10-20

2.  Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Authors:  Anita J Kumar; Phyllis A Gimotty; Joel M Gelfand; Georgina Buck; Jacob M Rowe; Anthony H Goldstone; Adele Fielding; David I Marks; Mark Litzow; Elisabeth Paietta; Hillard M Lazarus; Martin S Tallman; Selina M Luger; Alison W Loren
Journal:  Am J Hematol       Date:  2016-08-22       Impact factor: 10.047

3.  Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.

Authors:  Jinlin Song; Qiufei Ma; Wei Gao; Ze Cong; Jipan Xie; Zachary Zimmerman; Laura Belton; Janet Franklin; Stephen Palmer
Journal:  Adv Ther       Date:  2019-02-13       Impact factor: 3.845

4.  Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study.

Authors:  Renato Bassan; Dieter Hoelzer; Xavier Thomas; Pau Montesinos; Jiri Pavlu; Jan McKendrick; Amber Kudlac; Arie Barlev; Beth Barber; Ze Cong
Journal:  Adv Ther       Date:  2019-03-07       Impact factor: 3.845

5.  Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.

Authors:  Max S Topp; Anthony S Stein; Nicola Gökbuget; Heinz-August Horst; Nicolas Boissel; Giovanni Martinelli; Hagop Kantarjian; Monika Brüggemann; Yuqi Chen; Gerhard Zugmaier
Journal:  Cancer Med       Date:  2021-03-18       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.